Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2017 June;69(3) > Minerva Ginecologica 2017 June;69(3):250-8

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Ginecologica 2017 June;69(3):250-8

DOI: 10.23736/S0026-4784.17.04044-8

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers

Valentina GRISENDI, Antonio, La MARCA

Unit of Obstetrics and Gynecology, Mother-Infant Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy


PDF


INTRODUCTION: In assisted reproduction technologies (ART) the controlled ovarian stimulation (COS) therapy is the starting point from which a good oocytes retrieval depends. Treatment individualization is based on ovarian response prediction, which largely depends on a woman’s ovarian reserve. Anti-Müllerian hormone (AMH) and antral follicle count (AFC) are considered the most accurate and reliable markers of ovarian reserve.
EVIDENCE ACQUISITION: A literature search was carried out for studies that addressed the ability of AMH and AFC to predict poor and/or excessive ovarian response in IVF cycles.
EVIDENCE SYNTHESIS: According to the predicted response to ovarian stimulation (poor- normal- or high-response) is today possible not only to personalize pre-treatment counseling with the couple, but also to individualize the ovarian stimulation protocol, choosing among GnRH-agonists or antagonists for endogenous follicle-stimulating hormone (FSH) suppression and formulating the FSH starting dose most adequate for the single patients.
CONCLUSIONS: In this review we discuss how to choose the best COS therapy for the single patient, on the basis of the markers-guided ovarian response prediction.


KEY WORDS: Fertilization in vitro - Ovulation induction - Anti-Mullerian hormone

top of page